Early steroid treatment (within 6 weeks of symptom onset) in cerebral amyloid angiopathy-related inflammation was associated with greater functional status at follow-up and reduced vasogenic edema, while findings on mortality and recurrence were inconclusive.
Early steroid treatment was associated with significantly greater functional status at follow-up compared with delayed treatment.
Early steroid treatment was associated with significantly reduced vasogenic edema severity at follow-up.
No statistically significant difference in 12-month CAA-ri recurrence was found between early and delayed steroid treatment groups.
A higher mortality risk was suggested in the early steroid group, but this finding was not supported by complementary survival analyses.
Of 70 screened patients, 48 met eligibility criteria and were included in the analysis.
This research suggests that in patients with cerebral amyloid angiopathy-related inflammation (CAA-ri) — a brain condition where amyloid deposits trigger inflammation causing swelling and neurological symptoms — starting steroid treatment early (within 6 weeks of symptom onset) may lead to meaningfully better outcomes than delaying treatment. Specifically, patients who received early steroids had better functional ability (measured by the modified Rankin Scale) and less brain swelling on MRI scans at follow-up, compared to those whose treatment was delayed beyond 6 weeks. These findings held after statistical adjustments to account for differences between the two groups. However, the study did not find a clear difference between early and delayed treatment when it came to disease recurrence over 12 months. A higher rate of death appeared in the early treatment group, but the authors noted this finding was not consistent across different statistical analyses and is likely unreliable given the small number of patients studied. The study involved only 48 patients from three Italian hospitals and was retrospective in design, meaning it looked back at existing records rather than randomly assigning treatments, which limits the strength of its conclusions. This research suggests that the timing of steroid initiation in CAA-ri may matter for short-term recovery, and that starting treatment promptly after diagnosis could help patients regain function and reduce brain inflammation. The authors note that larger, prospective studies are needed to confirm these findings, clarify any mortality risks, and better understand long-term outcomes including disease recurrence.
Negro G, Rossi M, Cavarsaschi E, Orsani G, Storti B, Losa M, et al.. (2026). Early vs Delayed Steroid Treatment in Cerebral Amyloid Angiopathy-Related Inflammation: A Retrospective Cohort Study.. Neurology(R) neuroimmunology & neuroinflammation. https://doi.org/10.1212/NXI.0000000000200639